

Kristen C. Buteau

Partner

T +1 (617) 248-5209 | kbuteau@choate.com



Kristen also works with universities and research institutions to provide focused patent protection for innovative discoveries.

PRACTICE AREAS Patent Prosecution

IP Strategies

Life Sciences

RECOGNITION

- Massachusetts Super Lawyers "Rising Star"
- "One to Watch" by Best Lawyers in America

REPRESENTATIVE ENGAGEMENTS

- Advises clients on worldwide portfolio management and filing strategies.
- Counsels start-up clients on developing IP strategies and portfolio creation.
- Assists clients in determining inventorship of patents/applications.
- Conducts freedom-to-operate and competitive landscape analyses.
- Prepares applications for Hatch-Waxman patent term extensions.
- Developed IP protection strategies for a venture-backed company focused on disease-modifying therapeutics for treating neurological diseases by preventing axonal degeneration.
- Represents clients in the preparation and prosecution of patent applications directed to treatment of oncology and autoimmune diseases, with a particular focus on kinase inhibitors.
- Conducted IP due diligence in support of Tesaro's in-licensing and prosecution of a patent estate protecting rolapitant, a novel NK1 antagonist now approved for the treatment and prevention of delayed nausea and vomiting associated with repeated courses of emetogenic cancer chemotherapy.

EDUCATION

Suffolk University Law School JD, 2010, *Intellectual Property, magna cum laude*, with distinction

Northeastern University MS, 2005, Chemistry

Boston University BA, 2000, Chemistry

ADMISSIONS

Massachusetts

U.S. Patent & Trademark Office

- Represented Tesaro during IP due diligence in support of its \$87 million initial public offering.
- Represented Tesaro in several rounds of follow-on financing, totaling more than \$400 million.
- Represented Celgene Corporation in IP due diligence in support of its \$1.1 billion acquisition of Impact Biomedicines.
- *Momenta v. Amphastar et al., D. Mass.:* Represented Momenta Pharmaceuticals in a patent infringement action relating to innovative methods of processing therapeutic polysaccharides.
- Children's Medical Center Corporation v. Celgene Corporation, D. Mass.:

 Represented Celgene Corporation in a breach of contract litigation regarding exclusive license agreement related to Revlimid and Pomalyst.

PUBLICATIONS AND PRESENTATIONS

- "Mastering the Art of 'Tooting Your Own Horn': Valuable Tools for Self-Marketing as a Woman in the Life Sciences Industry and Being Your Own Best Advocate," panelist, ACI Women Leaders in Life Sciences Law Virtual Conference, November 2020.
- "Raising the Stakes in Patent Cases," *panelist*, BIO IPCC Fall Conference, November 2018.
- "The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors," co-author, Bioorganic & Medicinal Chemistry Letters.
- "Deuterated Drugs: Unexpectedly Nonobvious?," author, Journal of High Technology Law.

PROFESSIONAL AND COMMUNITY INVOLVEMENT

- Member of the American Chemical Society
- Member of the Boston Patent Law Association